TLD

DEVICE2 trials

Sponsors

University College, London, Hangzhou Broncus Medical Co., Ltd.

Conditions

COPDHIV InfectionsHIV-1-infectionHivPaediatric Human Immunodeficiency Virus Infection

Phase 3

Long-Acting Treatment in Adolescents (LATA)

Active, not recruitingNCT05154747

University College, LondonHiv, HIV-1-infection, HIV Infections +1

Start: 2023-06-22End: 2026-03-31Updated: 2024-04-29

Unknown Phase

Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD

RecruitingNCT05799664

Hangzhou Broncus Medical Co., Ltd.COPD

Start: 2023-07-04End: 2026-08-31Target: 200Updated: 2024-01-24

Related Papers

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.

2026-01-07

PA-257 ‘Nothing about us without us’: multi-country adolescent patient-led recruitment information in the long-acting treatment in adolescents (LATA) trial – an animated video to compliment ‘traditional’ participant information

2023-12-01